Ting Xu1,2, Kun Wu3, Lei Zhang4, Shutao Zheng5, Xiaopeng Wang3, Hao Zuo3, Xu Wu3, Guoquan Tao3, Baofei Jiang6, Li Zhang7. 1. The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, People's Republic of China. 2. The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China. 3. Department of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, No. 6, Huanghe West Road, Huai'an, 223300, Jiangsu Province, People's Republic of China. 4. Department of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China. 5. Clinical Medical Research Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China. 6. Department of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, No. 6, Huanghe West Road, Huai'an, 223300, Jiangsu Province, People's Republic of China. jbf1121@163.com. 7. VIP Medicine, The First Affiliated Hospital of Xinjiang Medical University, No. 137, Liyushan South Road, Urumqi, 830054, Xinjiang Uygur Autonomous Region, People's Republic of China. zhanglizl1969@yeah.net.
Abstract
BACKGROUND: Long non-coding RNAs (lncRNAs) are known to be frequently dysregulated in many types of human cancer. As yet, however, their roles in colon carcinogenesis have not been fully elucidated. In the current study, we assessed whether lncRNA LINC00858 may be involved in the progression of colon cancer and, in addition, investigated its downstream targets. METHODS: LINC00858 expression in patient-derived colon cancer tissues and in colon cancer cell lines was determined using RT-qPCR. Also, relationships between LINC00858 expression and various clinicopathological characteristics were analyzed. The subcellular localization of LINC00858 was determined using fluorescence in situ hybridization. Interactions between LINC00858 and its downstream targets were first predicted by bioinformatic analysis and, subsequently, confirmed by RNA pull-down, RNA immunoprecipitation, chromatin immunoprecipitation and dual luciferase reporter assays. After in vitro upregulation of LINC00858 and/or silencing of WNK2 and hepatocyte nuclear factor 4α (HNF4α), the biological behavior of colon cancer cells was assessed using 5-ethynyl-2'-deoxyuridine (EdU) incorporation, Transwell invasion and tube formation assays. In vivo cancer growth was evaluated in nude mice. RESULTS: We found that LINC00858 was highly expressed in primary colon cancer tissues and colon cancer cell lines, and was mainly located in the nucleus. High LINC00858 expression was found to correlate with a poor differentiation, advanced TNM stages and lymph node metastasis. Exogenous overexpression of LINC00858 promoted cell proliferation, invasion and migration of colon cancer cells, and facilitated angiogenesis and tumor growth. In addition, we found that LINC00858 can bind to and upregulate the nuclear transcription factor HNF4α, leading to WNK2 expression downregulation. This, in turn, resulted in the promotion of colon cancer cell growth. CONCLUSIONS: From our data we conclude that LINC00858 acts as a tumor-promoting lncRNA in colon cancer by upregulating HNF4α and downregulating WNK2. Our results may provide novel targets for the treatment for colon cancer.
BACKGROUND: Long non-coding RNAs (lncRNAs) are known to be frequently dysregulated in many types of humancancer. As yet, however, their roles in colon carcinogenesis have not been fully elucidated. In the current study, we assessed whether lncRNA LINC00858 may be involved in the progression of colon cancer and, in addition, investigated its downstream targets. METHODS:LINC00858 expression in patient-derived colon cancer tissues and in colon cancer cell lines was determined using RT-qPCR. Also, relationships between LINC00858 expression and various clinicopathological characteristics were analyzed. The subcellular localization of LINC00858 was determined using fluorescence in situ hybridization. Interactions between LINC00858 and its downstream targets were first predicted by bioinformatic analysis and, subsequently, confirmed by RNA pull-down, RNA immunoprecipitation, chromatin immunoprecipitation and dual luciferase reporter assays. After in vitro upregulation of LINC00858 and/or silencing of WNK2 and hepatocyte nuclear factor 4α (HNF4α), the biological behavior of colon cancer cells was assessed using 5-ethynyl-2'-deoxyuridine (EdU) incorporation, Transwell invasion and tube formation assays. In vivo cancer growth was evaluated in nude mice. RESULTS: We found that LINC00858 was highly expressed in primary colon cancer tissues and colon cancer cell lines, and was mainly located in the nucleus. High LINC00858 expression was found to correlate with a poor differentiation, advanced TNM stages and lymph node metastasis. Exogenous overexpression of LINC00858 promoted cell proliferation, invasion and migration of colon cancer cells, and facilitated angiogenesis and tumor growth. In addition, we found that LINC00858 can bind to and upregulate the nuclear transcription factor HNF4α, leading to WNK2 expression downregulation. This, in turn, resulted in the promotion of colon cancer cell growth. CONCLUSIONS: From our data we conclude that LINC00858 acts as a tumor-promoting lncRNA in colon cancer by upregulating HNF4α and downregulating WNK2. Our results may provide novel targets for the treatment for colon cancer.
Authors: Sónia Moniz; Olga Martinho; Filipe Pinto; Bárbara Sousa; Cláudia Loureiro; Maria José Oliveira; Luís Ferreira Moita; Mrinalini Honavar; Célia Pinheiro; Manuel Pires; José Manuel Lopes; Chris Jones; Joseph F Costello; Joana Paredes; Rui Manuel Reis; Peter Jordan Journal: Hum Mol Genet Date: 2012-10-03 Impact factor: 6.150
Authors: Chibo Hong; K Scott Moorefield; Peter Jun; Kenneth D Aldape; Samir Kharbanda; Heidi S Phillips; Joseph F Costello Journal: Proc Natl Acad Sci U S A Date: 2007-06-19 Impact factor: 11.205
Authors: Peter Jun; Chibo Hong; Anita Lal; Judith M Wong; Michael W McDermott; Andrew W Bollen; Christoph Plass; William A Held; Dominic J Smiraglia; Joseph F Costello Journal: Neuro Oncol Date: 2008-11-11 Impact factor: 12.300
Authors: M P Coleman; D Forman; H Bryant; J Butler; B Rachet; C Maringe; U Nur; E Tracey; M Coory; J Hatcher; C E McGahan; D Turner; L Marrett; M L Gjerstorff; T B Johannesen; J Adolfsson; M Lambe; G Lawrence; D Meechan; E J Morris; R Middleton; J Steward; M A Richards Journal: Lancet Date: 2010-12-21 Impact factor: 79.321